Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
24.52-0.03 (-0.12%)
At close: 05:39PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.55
Open24.80
Bid24.46 x N/A
Ask24.51 x N/A
Day's Range24.23 - 24.85
52 Week Range23.40 - 47.60
Volume1,539,323
Avg. Volume1,207,283
Market Cap13.72B
Beta (5Y Monthly)1.13
PE Ratio (TTM)7.64
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.92 (3.75%)
Ex-Dividend DateMay 16, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FRE.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Fresenius Medical shares at 12-year low as labour costs weigh on profit

      (Reuters) -Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S. staff shortage leaves it scrambling for nurses. In an unscheduled statement late on Wednesday, FMC flagged a decline in net income approaching 20% this year and withdrew its 2025 targets. Most of its U.S. patients are covered by state-run insurer Medicare, with lump-sum reimbursements per patient that only get adjusted to cost inflation with a two-year delay, the chief executive of FMC parent Fresenius, Stephan Sturm, said on an analyst call.

    • Zacks

      After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)

      The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Advertisement
    Advertisement